loading...| Preferred Name |
denosumab |
|
| Synonyms |
|
|
| ID |
http://purl.obolibrary.org/obo/dinto_DB06643 |
|
| AHFScode |
92:24 |
|
| ATCCode |
M05BX04 |
|
| CASRN |
615258-40-7 |
|
| DBBrand |
ranmark prolia xgeva |
|
| DBSynonym |
amg-162 |
|
| Definition |
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and 2 light chains. Each light chain consists of 215 amino acids. Each heavy chain consists of 448 amino acids with 4 intramolecular disulfides. FDA approved on June 1, 2010. |
|
| has pharmacological target | ||
| label |
denosumab |
|
| may interact with |
http://purl.obolibrary.org/obo/dinto_DB08879 |
|
| prefixIRI |
obo2:dinto_DB06643 |
|
| prefLabel |
denosumab |
|
| related with | ||
| xref |
PharmGKB:PA166048634 National Drug Code Directory:55513-710-01 RxList:http://www.rxlist.com/prolia-drug.htm Drugs.com:http://www.drugs.com/ppa/denosumab.html Wikipedia:http://en.wikipedia.org/wiki/Denosumab |
|
| subClassOf |